Latest Insider Transactions at Nephros Inc (NEPH)
This section provides a real-time view of insider transactions for Nephros Inc (NEPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEPHROS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEPHROS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2024
|
Arthur H Amron Director |
BUY
Open market or private purchase
|
Direct |
3,000
+2.82%
|
$6,000
$2.24 P/Share
|
|
May 28
2024
|
Arthur H Amron Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.95%
|
$4,000
$2.22 P/Share
|
|
May 16
2024
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+41.67%
|
$100,000
$2.24 P/Share
|
|
Mar 13
2024
|
Wexford Capital LP |
SELL
Other acquisition or disposition
|
Direct |
91,463
-62.0%
|
-
|
|
Mar 13
2024
|
Arthur H Amron Director |
BUY
Other acquisition or disposition
|
Direct |
91,463
+48.16%
|
-
|
|
Mar 12
2024
|
Arthur H Amron Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$14,000
$2.45 P/Share
|
|
Dec 13
2023
|
Arthur H Amron Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,291
+50.0%
|
-
|
|
Dec 13
2023
|
Joseph Michael Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,291
+34.43%
|
-
|
|
Dec 13
2023
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,291
+16.04%
|
-
|
|
Dec 13
2023
|
Oliver J. Spandow Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,294
+14.91%
|
-
|
|
Dec 07
2023
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
18,000
+47.37%
|
$36,000
$2.2 P/Share
|
|
Aug 15
2023
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
1,901
+48.73%
|
$1,901
$1.69 P/Share
|
|
Aug 14
2023
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
99
+50.0%
|
$99
$1.5 P/Share
|
|
Jan 05
2023
|
Joseph Michael Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,402
+50.0%
|
-
|
|
Jan 05
2023
|
Arthur H Amron Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,613
+50.0%
|
-
|
|
Jan 05
2023
|
Tom Gwydir Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,613
+38.98%
|
-
|
|
Jan 05
2023
|
Oliver J. Spandow Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,481
+38.69%
|
-
|
|
Jan 05
2023
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,613
+41.24%
|
-
|
|
Mar 05
2022
|
Andrew Astor President, CEO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,815
+13.77%
|
$29,630
$2.7 P/Share
|
|
Feb 16
2022
|
Wesley S. Lobo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,389
-15.37%
|
$25,556
$4.8 P/Share
|
|
Dec 14
2021
|
Arthur H Amron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,582
+50.0%
|
-
|
|
Dec 14
2021
|
Oliver J. Spandow Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,429
+17.94%
|
-
|
|
Dec 14
2021
|
Tom Gwydir Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,582
+22.69%
|
-
|
|
Dec 14
2021
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,582
+28.1%
|
-
|
|
Aug 20
2021
|
Wesley S. Lobo Chief Marketing Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+2.35%
|
$7,000
$7.92 P/Share
|
|
Aug 18
2021
|
Tom Gwydir Director |
BUY
Open market or private purchase
|
Direct |
5,000
+31.19%
|
$35,000
$7.64 P/Share
|
|
Aug 18
2021
|
Andrew Astor President, CEO & CFO |
BUY
Open market or private purchase
|
Direct |
2,500
+3.11%
|
$17,500
$7.77 P/Share
|
|
Aug 17
2021
|
Andrew Astor President, CEO & CFO |
BUY
Open market or private purchase
|
Direct |
2,500
+3.21%
|
$17,500
$7.67 P/Share
|
|
Jun 01
2021
|
Wexford Capital LP |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
66,667
+1.85%
|
$133,334
$2.7 P/Share
|
|
May 24
2021
|
Daron Evans CEO of Specialty Renal Product |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,222
+10.82%
|
$4,444
$2.7 P/Share
|
|
Feb 16
2021
|
Wesley S. Lobo Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,557
+50.0%
|
-
|
|
Jan 27
2021
|
Wexford Capital LP |
BUY
Exercise of conversion of derivative security
|
Direct |
14,754
+3.54%
|
$59,016
$4.21 P/Share
|
|
Jan 06
2021
|
Arthur H Amron Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,666
+50.0%
|
-
|
|
Jan 06
2021
|
Oliver J. Spandow Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,666
+15.89%
|
-
|
|
Jan 06
2021
|
Malcolm C Persen Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,921
+10.83%
|
-
|
|
Jan 06
2021
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,666
+33.92%
|
-
|
|
Jan 06
2021
|
Tom Gwydir Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,666
+37.81%
|
-
|
|
Jan 06
2021
|
Wexford Capital LP |
BUY
Grant, award, or other acquisition
|
Direct |
3,196
+50.0%
|
-
|
|
Nov 19
2020
|
Andrew Astor President, CEO & CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+1.35%
|
$5,000
$5.87 P/Share
|
|
Nov 18
2020
|
Oliver J. Spandow Director |
BUY
Open market or private purchase
|
Direct |
1,500
+8.7%
|
$7,500
$5.83 P/Share
|
|
Oct 15
2020
|
Wexford Capital LP |
BUY
Grant, award, or other acquisition
|
Indirect |
166,667
+4.42%
|
$1,000,002
$6.0 P/Share
|